Navigation Links
String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline
Date:7/28/2014

igate diseases in a variety of unmet needs, including brain tumors. We see our current collaboration with Dr. Sampson and Mitchells’ laboratories as a step in that direction, where we hope to share our knowledge about LAMP and our resources to further enable the potentially breakthrough vaccine work that he is conducting in this devastating disease.”

Classified as a Grade IV astrocytoma, GBM develops from the lineage of star-shaped glial cells called astrocytes, which support nerve cells. GBM are also known as the most aggressive of a group of tumors referred to as high-grade gliomas. Patients with GBM have a poor prognosis and usually survive less than 15 months following diagnosis. The current standard of care consists of surgical debulking (full resection is nearly impossible due to the highly infiltrative nature of the cancerous cells into healthy brain tissue), followed by chemotherapy (temozolomide), and radiation. Currently there are no effective long-term treatments for this disease.

About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit, http://www.immunomix.com.

About National Brain Tumor Society
National Bra
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
2. Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
3. Neuroprotection - Drugs, Markets and Companies - Updated 2013 Report with Extra Company Collaborations
4. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
5. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
6. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
7. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
8. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
11. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... SAN DIEGO , Aug. 27, 2015 ... second annual meeting of the Japan Society of HTLV-1, ... Science Institute Auditorium. The purpose of the Society is ... well as the development of medical technology and research ... health and welfare. "HUYA is proud to ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's ... narrows down the product choices to a manageable shortlist of bench and floor ... to models that fit best with the customer’s industry and application. , ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, ... second US laboratory is to open in Manhattan, Kansas in early October, 2015. ... long-term growth of research and development through collaboration with researchers from Kansas State ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... 10 /PRNewswire-FirstCall/ - Mr. Pierre,Fitzgibbon, President and Chief ... "Company", TSX: ATB) today announced changes to the,management ... by Mr.,Richard Bordeleau, President of the Health & ... pursue news challenges. However, Mr. Bordeleau,will continue to ...
... Audio Webcast Tuesday, September 11, 2007, SAN DIEGO, ... announced today that Neurocrine Biosciences will,present at the Bear ... 11, 2007 at 10:30 a.m. Eastern Time (ET),/7:30 a.m. ... may be accessed on the Company,s website at, http://www.neurocrine.com ...
... the Treatment of Opioid ... ... (Nasdaq: NKTR ) presented results today at the American ... 1 trial of NKTR-118 (oral PEG-naloxol). NKTR-118 is Nektar,s,proprietary investigational ...
Cached Biology Technology:Atrium Innovations Announces Management Changes 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 3Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 4Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 5
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... researchers at the University of California, Davis, have demonstrated that ... in rocks, boosting the trees, growth and their ability to ... carbon dioxide is the most important climate-change gas, the nitrogen ... warm in the future, the researchers say. They report their ...
... LA JOLLA, CA September 1, 2011 Examining ... deprived of oxygen, researchers at The Scripps Research Institute have ... to the specific action of a naturally occurring fatty molecule ... young brain cells. This observation made in mice suggests ...
... of breast cancer dropped significantly in mice when their regular ... report in the journal Nutrition and Cancer . ... C. Edwards School of Medicine, compared the effects of a ... through the mother from conception through weaning, and then through ...
Cached Biology News:Bedrock nitrogen may help forests buffer climate change, study finds 2Bedrock nitrogen may help forests buffer climate change, study finds 3Discovery suggests way to block fetal brain damage produced by oxygen deprivation 2Discovery suggests way to block fetal brain damage produced by oxygen deprivation 3Breast cancer risk drops when diet includes walnuts, Marshall researchers find 2
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
... Mouse Monoclonal to L1 Cell Adhesion Molecule ... is located in Xq28, is involved in ... the aqueduct of Sylvius); 2) MASA (mental ... 3) SPG1 (spastic paraplegia). Immunogen: ...
...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: